Whole-of-business quality management software for Australian pharmaceutical companies

Whole-of-business quality management software is a single platform that unifies document control, corrective and preventive action (CAPA), batch release, training and competency, supplier quality and regulatory intelligence, so a pharmaceutical manufacturer can demonstrate compliance across every applicable standard from one connected system rather than a set of disconnected tools

Australian manufacturers face a specific version of this challenge: domestic PIC/S GMP obligations under the Therapeutic Goods Act 1989, layered with FDA 21 CFR Part 11, EU Annex 11, ISO 13485 and ICH Q7 to Q10 the moment a company exports or partners internationally, with TGA enforcement active enough that license approvals, suspensions and revocations appear in the same publication cycle. 

TGA and PIC/S compliance requirements for Australian pharmaceutical manufacturers 

Domestic GMP obligations under the Therapeutic Goods Act 

Under Section 38 of the Therapeutic Goods Act 1989, every Australian pharmaceutical manufacturer must hold a TGA manufacturing license.

Because Australia belongs to the Pharmaceutical Inspection Co-operation Scheme (PIC/S), that license depends on compliance with the PIC/S GMP guide, most recently revised as PE009-13. For a manufacturer supplying only the domestic market, this can, in principle, be a single-standard compliance exercise. 

The international standards layer once a manufacturer exports or partners overseas 

Few manufacturers stop there. Any Australian company that exports finished product, licenses technology from an overseas partner, or supplies a multinational sponsor typically has to demonstrate GxP compliance against FDA 21 CFR Part 11, EU Annex 11, ISO 13485 and the ICH Q7 to Q10 quality guidelines as well.

That exposure is not theoretical: the TGA and FDA operate under a mutual recognition and information-exchange arrangement covering GMP inspections, so a finding in one jurisdiction can carry weight in the other. 

Market growth and regulatory pressure on Australian pharmaceutical manufacturing 

Market growth to 2030 

Australia's pharmaceutical market is valued at roughly AUD 22.4 billion as of 2025, with most forecasts putting growth at 5.9 to 7.4 percent CAGR through the rest of the decade, driven by an ageing population and an expanding Pharmaceutical Benefits Scheme. 

Onshore manufacturing and API import dependence 

Australia still imports roughly 90 percent of its active pharmaceutical ingredients, and government grants are now underwriting local API and biologics capacity, including antimicrobials, injectables and mRNA vaccines, specifically to reduce that dependence. Every new onshore facility funded by that push adds another manufacturing site, another TGA license and another quality system that has to hold up under inspection from day one. 

How the TGA enforces pharmaceutical manufacturing licenses 

A manufacturing license decision is the process by which the TGA reviews, grants, varies, suspends or revokes a pharmaceutical manufacturer's authority to produce therapeutic goods in Australia.

Recent publication cycles have included new license approvals alongside suspensions and revocations in the same release: a risk-based, continuously enforced environment, not a certification earned once and filed away.

A quality system that only reflects a manufacturer's state at the last audit is not built for that environment; a whole-of-business system needs to show live compliance status across every site and standard, continuously. 

What is whole-of-business quality management software? 

Whole-of-business quality management is a single software platform that unifies document control, CAPA, batch record and release management, audits, training and competency records, supplier quality and regulatory intelligence into one connected system, rather than a set of standalone tools bolted together by department.

It differs from a narrower pharmaceutical quality management system that covers only one function, such as document control alone, because most quality failures come from the gaps between controls: a CAPA closed in one system that never updates the training record in another, or a supplier finding that never reaches the team responsible for updating the affected specification. 

Which standards does a whole-of-business QMS need to satisfy? 

The table below maps the standards an Australian pharmaceutical manufacturer with any international exposure typically has to satisfy, and what each one requires of a quality system in practice. 

Standard	What it requires	What it means for the business
TGA / PIC/S GMP (PE009-13)	Documented, controlled manufacturing processes with full traceability	Baseline license condition for any Australian manufacturing site
FDA 21 CFR Part 11	Validated electronic records and signatures with a complete audit trail	Required for any product exported to, or reviewed by, the US market
EU Annex 11	Computerised systems validated and risk-assessed across their lifecycle	Required for manufacturers supplying or partnering into the EU
ISO 13485	A certified quality management system specific to medical devices	Applies where a pharmaceutical business also touches devices or combination products
ICH Q7 to Q10	Risk-based quality management spanning API manufacture through to pharmaceutical quality systems	The connective framework regulators expect between GMP and a mature quality system

Core capabilities of a whole-of-business quality management system 

A platform only qualifies as whole-of-business quality management if it covers the following as one connected system rather than as separate tools: 

• Document control: version-controlled, audit-ready SOPs and specifications with full change history 
• Batch record and release management: structured batch review and release workflows with an end-to-end audit trail 
• CAPA management: corrective and preventive actions tracked from root cause through to verified effectiveness 
• Audit management: internal, supplier and regulatory audits scheduled, executed and closed out in one system 
• Training and competency: role-based training records that update automatically when a linked procedure or CAPA changes 
• Supplier quality management: qualification, performance monitoring and audit history in one record per supplier 
• Regulatory intelligence: a live view of which standards apply to which site, product and market, and where a gap exists 

Case studies: pharmaceutical manufacturers using a whole-of-business QMS 

These manufacturers were measured against GMP and ICH-aligned requirements that map directly onto what TGA and PIC/S expect of Australian manufacturers, even though none of this evidence comes from an Australian deployment yet.

Symbiosis Pharmaceutical Services: securing an MHRA manufacturing license 

Symbiosis Pharmaceutical Services is a contract manufacturer of injectable pharmaceuticals for clinical trials, and needed a validated quality system in place before it could secure the MHRA manufacturing license required to begin production.

Symbiosis implemented Q-Pulse, now Ideagen Quality Management, to manage document control, auditing and corrective and preventive actions in a single system. That implementation directly supported its MHRA license approval, the same category of manufacturing authorization that a TGA license represents in Australia, granted against equivalent GMP expectations. 

Lexicon Pharmaceuticals: cutting document review turnaround 

Lexicon Pharmaceuticals, a biopharmaceutical company running multiple drug programs, needed to speed up document review without losing control of version history or audit trails.

Using Ideagen PleaseReview for real-time collaboration, Lexicon cut document review turnaround to roughly a third of its previous timeline across more than 20 reviewers, while maintaining a 21 CFR Part 11 audit trail throughout. 

Torbay Pharmaceuticals: centralizing compliance across multiple sites 

Torbay Pharmaceuticals centralized CAPA, calibration and training management across three manufacturing sites using Ideagen Quality Management, sustaining EU GMP compliance across all three.

That multi-site pattern is the closest existing proof point to what a whole-of-business QMS needs to deliver for an Australian manufacturer running more than one TGA-licensed site: one connected system reflecting live compliance status everywhere at once, rather than separate site systems reporting back after the fact. 

Choosing a whole-of-business QMS for Australian pharmaceutical manufacturing 

The most useful test for evaluating a whole-of-business QMS is not a checklist of standards but whether it can show, on demand, how a single change, such as a revised SOP or a closed CAPA, has flowed through every affected record across every applicable standard.

Ideagen's quality management platform, built on the same architecture as its Q-Pulse predecessor, is one option built specifically to answer that test, with published support for GMP, ICH Q7 to Q10, FDA 21 CFR Part 11, EU Annex 11, ISO 9001 and ISO 13485, integration with Veeva Vault, and document collaboration through PleaseReview for teams managing regulatory submissions alongside it. 

For a manufacturer weighing onshore expansion against a rising compliance burden, that kind of connected, whole-of-business visibility is no longer a convenience. It is the baseline the TGA's own enforcement pattern is already asking for.